Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 January 2005, Vol. 105, No. 2, pp. 434.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Noy, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Noy, A.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow


InsideBlood

CLINICAL OBSERVATIONS

Comment on Hegde et al, page 496

Occult leptomeningeal NHL: go with the flow?

Ariela Noy

MEMORIAL SLOAN-KETTERING CANCER CENTER

Patients with aggressive non-Hodgkin lymphoma (NHL) are at risk for leptomeningeal disease. Hegde and colleagues shed light on who is at risk and how we detect occult disease.

Leptomeningeal disease from aggressive lymphoma is most often a fatal complication. Clinical paradigms exist to predict who will develop this complication, but they are inaccurate and not widely followed. Moreover, prophylactic intrathecal therapy for high-risk patients is cumbersome and invasive. Finally, the sensitivity of cytology is only between 40% to 80%,1,2 so many patients who already have leptomeningeal spread at diagnosis of systemic non-Hodgkin lymphoma (NHL) are missed and often only receive ineffective prophylactic dosing rather than treatment.

In this issue, Hegde and colleagues suggest that occult leptomeningeal disease at presentation and at relapse can be detected in high-risk patients using multicolor flow cytometry. In the newly diagnosed cohort, 11 of 51 (22%) of patients had a positive cerebrospinal fluid (CSF) by flow, yet only 1 was detected by routine cytology. The CSF fluid in these samples contained a median of only 0.002 x 109/L (2/µL) white blood cells (WBCs), and only 7% of the cells were characterized as malignant. Patients at high risk, but with negative cytology, received 12 prophylactic intrathecal therapies in addition to chemotherapy without blood-brain penetration, while the 10 with flow-positive occult disease and the 1 with a positive cytology received an intensive treatment beginning with therapy twice weekly and concluding with maintenance. In the 10 patients with follow-up at the National Institutes of Health (NIH), 7 received intrathecal via lumbar puncture and 3, via Ommaya reservoir.

Despite this very aggressive strategy, 5 (45%) relapsed in the central nervous system and died. In contrast, in patients at increased risk of central nervous system involvement, but with negative flow cytometry, the relapse risk was only 8% (3/40). Additionally, all 3 patients with relapsed systemic disease and positive CSF flow cytometry died.

This study demonstrates that flow cytometry is more sensitive than cytology in detecting occult leptomeningeal disease at diagnosis of systemic NHL with high-risk features. Importantly, Hegde et al demonstrate that 2 or more extranodal sites are the prime determinant in predicting occult or overt leptomeningeal disease, a factor commensurate with the biology of the disease. However, are these results widely applicable and should all patients deemed to be at risk have CSF sent for flow cytometry? It is certainly notable that 45% of the patients in this study had HIV, although only 64% of those with positive CSF fluid had HIV. Consequently, a prospective multi-institutional study in both HIV-positive and -negative individuals would prove that this approach can be generalized. It would also help answer the question as to whether aggressive intrathecal therapy can be more efficacious in those with flow-positive CSF if given via Ommaya or if agents with longer half-lives such as rituximab or liposomal cytarabine are used.Go {blacksquare}



Burkitt's lymphoma in the cerebrospinal fluid.

 

References

  1. Schiff D, Feske SK, Wen PY. Deceptively normal ventricular fluid in lymphomatous meningitis. Arch Intern Med. 1993;153: 389-390.[Abstract/Free Full Text]

  2. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29: 1369-1375.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology
Upendra Hegde, Armando Filie, Richard F. Little, John E. Janik, Nicole Grant, Seth M. Steinberg, Kieron Dunleavy, Elaine S. Jaffe, Andrea Abati, Maryalice Stetler-Stevenson, and Wyndham H. Wilson
Blood 2005 105: 496-502. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Noy, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Noy, A.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020